Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $27.79 USD
Change Today +0.20 / 0.72%
Volume 432.2K
IMS On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

ims health holdings inc (IMS) Key Developments

IMS Health Holdings, Inc. Announces Preliminary Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Full Year of 2015

IMS Health Holdings, Inc. announced preliminary unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $632 million against $645 million a year ago. Operating Income was $91 million against $67 million a year ago. Income before income taxes was $58 million against loss before income taxes of $37 million a year ago. Net income was $298 million against net loss of $24 million a year ago. Diluted earnings per share attributable to common shareholders were $0.86 against diluted loss per share attributable to common shareholders of $0.09 a year ago. Net cash provided by operating activities was $30 million against cash used in operating activities of $103 million a year ago. Capital expenditures were $9 million against $33 million a year ago. Adjusted EBITDA was $216 million against $217 million a year ago. Adjusted net income was $136 million against $70 million a year ago, the increase primarily due to lower interest expense and lower cash taxes. Adjusted pre-tax income was $145 million against $99 million a year ago. Diluted adjusted earnings per share attributable to common shareholders were $0.39 against $0.24 a year ago. Net debt was $3,330 million. Unlevered Free Cash Flow for the first quarter was $57 million, up $68 million from the same period last year. For 2015, the company reaffirms full-year 2015 constant currency guidance. The company expects core IMS Health (excluding the impact of the acquisition of Cegedim’s CRM and Strategic Data businesses) to have full-year 2015 constant currency growth of 5% to 6% in revenue, 7.5% to 8.5% in Adjusted EBITDA, 16 to 19% in Adjusted Net Income, and 11% to 14% in Adjusted Diluted Earnings per Share. Including the acquisition of Cegedim’s CRM and Strategic Data businesses (Combined business), IMS Health expects to have full-year 2015 constant currency growth of 19% to 20% in revenue, 13% to 14% in Adjusted EBITDA, 20% to 23% in Adjusted Net Income, and 15% to 18% in Adjusted Diluted Earnings per Share.

IMS Health Holdings, Inc. to Report Q1, 2015 Results on Apr 24, 2015

IMS Health Holdings, Inc. announced that they will report Q1, 2015 results Pre-Market on Apr 24, 2015

IMS Health Holdings, Inc., Q1 2015 Earnings Call, Apr 24, 2015

IMS Health Holdings, Inc., Q1 2015 Earnings Call, Apr 24, 2015

IMS Health Holdings, Inc. Announces Executive Appointments, Effective April 1, 2015

IMS Health Holdings, Inc. appointed Kevin Knightly as Senior Vice President, Information Offerings, effective April 1, 2015. Mr. Knightly was previously Senior Vice President, Supplier Management. Robert Chu has been appointed Senior Vice President, Technology Solutions effective April 1, 2015. Mr. Chu is President, IMS Health Asia Pacific and previously was General Manager of IMS France. Earlier in his career, he spent 15 years at IBM Corporation in sales, consulting and technology leadership roles. Also effective April 1, Satwinder Sian, formerly Senior Vice President, Global Technology Operations, has been named strategic advisor to the Chief Executive Officer.

IMS Health Announces Pricing of €275 Million Senior Notes, Due April 1, 2023

IMS Health Holdings, Inc. announced the pricing of its offering of €275 million in gross proceeds of senior notes to be issued by IMS Health Incorporated. The net proceeds from the notes offering will be used to fund a portion of the purchase price for IMS Health’s previously announced proposed acquisition of certain customer relationship management and strategic data businesses of Cegedim, SA and for related fees and expenses. The notes will bear interest at a rate of 4.125% and will pay interest semi-annually in arrears on October 1 and April 1 of each year beginning on October 1, 2015. The notes will mature on April 1, 2023. The notes are being offered only to qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act of 1933 and outside the United States only to non-U.S. investors pursuant to Regulation S.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMS:US $27.79 USD +0.20

IMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Informatica Corp $48.10 USD +0.03
PAREXEL International Corp $64.66 USD +1.08
Quintiles Transnational Holdings Inc $67.30 USD +1.42
Teradata Corp $45.01 USD +1.02
Verisk Analytics Inc $75.71 USD +0.67
View Industry Companies
 

Industry Analysis

IMS

Industry Average

Valuation IMS Industry Range
Price/Earnings 70.1x
Price/Sales 3.5x
Price/Book 5.2x
Price/Cash Flow 16.6x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMS HEALTH HOLDINGS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.